title: Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.
authors.affiliation: Department of Medical Oncology, Erasmus Medical Center/Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands. m.dejonge@erasmusmc.nl
authors.forename: M J A
authors.initials: MJ
authors.lastname: de Jonge
authors.forename: S
authors.initials: S
authors.lastname: Kaye
authors.forename: J
authors.initials: J
authors.lastname: Verweij
authors.forename: C
authors.initials: C
authors.lastname: Brock
authors.forename: S
authors.initials: S
authors.lastname: Reade
authors.forename: M
authors.initials: M
authors.lastname: Scurr
authors.forename: L
authors.initials: L
authors.lastname: van Doorn
authors.forename: C
authors.initials: C
authors.lastname: Verheij
authors.forename: W
authors.initials: W
authors.lastname: Loos
authors.forename: C
authors.initials: C
authors.lastname: Brindley
authors.forename: P
authors.initials: P
authors.lastname: Mistry
authors.forename: M
authors.initials: M
authors.lastname: Cooper
authors.forename: I
authors.initials: I
authors.lastname: Judson
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010619:Phenazines / Q000493:pharmacokinetics* / Q000627:therapeutic use; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors
chemical_list: C446952:4-methoxybenzo(a)phenazine-11-carboxylic acid (2-(dimethylamino)-1-methylethyl)amide; D004791:Enzyme Inhibitors; D010619:Phenazines; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors